Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 48.25
INCY's Cash-to-Debt is ranked lower than
51% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. INCY: 48.25 )
Ranked among companies with meaningful Cash-to-Debt only.
INCY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.35  Med: 1.49 Max: No Debt
Current: 48.25
0.35
No Debt
Equity-to-Asset 0.71
INCY's Equity-to-Asset is ranked higher than
55% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. INCY: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
INCY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.21 Max: 0.92
Current: 0.71
-1.83
0.92
Debt-to-Equity 0.02
INCY's Debt-to-Equity is ranked higher than
93% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. INCY: 0.02 )
Ranked among companies with meaningful Debt-to-Equity only.
INCY' s Debt-to-Equity Range Over the Past 10 Years
Min: -17.62  Med: 0 Max: 97.27
Current: 0.02
-17.62
97.27
Debt-to-EBITDA -0.24
INCY's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. INCY: -0.24 )
Ranked among companies with meaningful Debt-to-EBITDA only.
INCY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -14.97  Med: 1.55 Max: 173.16
Current: -0.24
-14.97
173.16
Piotroski F-Score: 5
Altman Z-Score: 12.93
Beneish M-Score: -3.07
WACC vs ROIC
9.70%
-38.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -11.11
INCY's Operating Margin % is ranked higher than
65% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. INCY: -11.11 )
Ranked among companies with meaningful Operating Margin % only.
INCY' s Operating Margin % Range Over the Past 10 Years
Min: -4064.53  Med: -2.74 Max: 14.69
Current: -11.11
-4064.53
14.69
Net Margin % -10.90
INCY's Net Margin % is ranked higher than
63% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. INCY: -10.90 )
Ranked among companies with meaningful Net Margin % only.
INCY' s Net Margin % Range Over the Past 10 Years
Min: -4565.45  Med: -19.57 Max: 9.43
Current: -10.9
-4565.45
9.43
ROE % -11.93
INCY's ROE % is ranked higher than
58% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. INCY: -11.93 )
Ranked among companies with meaningful ROE % only.
INCY' s ROE % Range Over the Past 10 Years
Min: -30.55  Med: 14.59 Max: 35.29
Current: -11.93
-30.55
35.29
ROA % -8.17
INCY's ROA % is ranked higher than
63% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. INCY: -8.17 )
Ranked among companies with meaningful ROA % only.
INCY' s ROA % Range Over the Past 10 Years
Min: -70.43  Med: -14.67 Max: 7.88
Current: -8.17
-70.43
7.88
ROC (Joel Greenblatt) % -64.65
INCY's ROC (Joel Greenblatt) % is ranked higher than
62% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. INCY: -64.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INCY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4727.38  Med: -73.03 Max: 115.22
Current: -64.65
-4727.38
115.22
3-Year Revenue Growth Rate 35.10
INCY's 3-Year Revenue Growth Rate is ranked higher than
82% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. INCY: 35.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INCY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.4  Med: 25.5 Max: 523.4
Current: 35.1
-61.4
523.4
3-Year EPS without NRI Growth Rate -74.10
INCY's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. INCY: -74.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INCY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.7 Max: 45.1
Current: -74.1
0
45.1
GuruFocus has detected 2 Warning Signs with Incyte Corp INCY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INCY's 30-Y Financials

Financials (Next Earnings Date: 2018-08-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

INCY Guru Trades in Q3 2017

Leon Cooperman 100,000 sh (New)
Paul Tudor Jones 17,943 sh (New)
Stanley Druckenmiller 75,400 sh (New)
Manning & Napier Advisors, Inc 1,071,325 sh (New)
Caxton Associates 2,200 sh (New)
Steven Cohen 164,600 sh (+723.00%)
Joel Greenblatt 121,896 sh (+73.02%)
Vanguard Health Care Fund 9,466,973 sh (+2.18%)
Ron Baron 10,630 sh (+0.31%)
Eaton Vance Worldwide Health Sciences Fund 176,462 sh (unchged)
Frank Sands 7,569,964 sh (-5.18%)
Mario Gabelli 2,400 sh (-7.69%)
Ken Fisher 14,022 sh (-9.72%)
Pioneer Investments 75,148 sh (-83.62%)
» More
Q4 2017

INCY Guru Trades in Q4 2017

Jim Simons 756,400 sh (New)
Pioneer Investments 471,468 sh (+527.39%)
Frank Sands 8,191,287 sh (+8.21%)
Vanguard Health Care Fund 9,466,973 sh (unchged)
Stanley Druckenmiller Sold Out
Ron Baron Sold Out
Leon Cooperman Sold Out
Caxton Associates Sold Out
Joel Greenblatt Sold Out
Ken Fisher 13,671 sh (-2.50%)
Mario Gabelli 2,300 sh (-4.17%)
Steven Cohen 70,000 sh (-57.47%)
Paul Tudor Jones 7,006 sh (-60.95%)
Eaton Vance Worldwide Health Sciences Fund 124,411 sh (-29.50%)
» More
Q1 2018

INCY Guru Trades in Q1 2018

Paul Tudor Jones 32,198 sh (+359.58%)
Mario Gabelli 2,800 sh (+21.74%)
Jim Simons 920,600 sh (+21.71%)
Frank Sands 9,768,698 sh (+19.26%)
Pioneer Investments 504,957 sh (+7.10%)
Vanguard Health Care Fund 9,466,973 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 124,411 sh (unchged)
Steven Cohen 55,000 sh (-21.43%)
Ken Fisher 6,104 sh (-55.35%)
» More
Q2 2018

INCY Guru Trades in Q2 2018

Ken Fisher 7,123 sh (+16.69%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Add 16.69%$60.85 - $83.98 $ 70.233%7,123
Ken Fisher 2018-03-31 Reduce -55.35%$83.06 - $100.98 $ 70.23-22%6,104
Mario Gabelli 2018-03-31 Add 21.74%$83.06 - $100.98 $ 70.23-22%2,800
Ken Fisher 2017-12-31 Reduce -2.50%$93.56 - $116.6 $ 70.23-33%13,671
Mario Gabelli 2017-12-31 Reduce -4.17%$93.56 - $116.6 $ 70.23-33%2,300
Joel Greenblatt 2017-12-31 Sold Out 0.21%$93.56 - $116.6 $ 70.23-33%0
Leon Cooperman 2017-12-31 Sold Out 0.45%$93.56 - $116.6 $ 70.23-33%0
Ron Baron 2017-12-31 Sold Out 0.01%$93.56 - $116.6 $ 70.23-33%0
Vanguard Health Care Fund 2017-09-30 Add 2.18%0.05%$109.15 - $138.27 $ 70.23-45%9,466,973
Joel Greenblatt 2017-09-30 Add 73.02%0.09%$109.15 - $138.27 $ 70.23-45%121,896
Leon Cooperman 2017-09-30 New Buy0.45%$109.15 - $138.27 $ 70.23-45%100,000
Ken Fisher 2017-09-30 Reduce -9.72%$109.15 - $138.27 $ 70.23-45%14,022
Ron Baron 2017-09-30 Add 0.31%$109.15 - $138.27 $ 70.23-45%10,630
Mario Gabelli 2017-09-30 Reduce -7.69%$109.15 - $138.27 $ 70.23-45%2,400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541714    SIC: 8731
Compare:OCSE:GEN, OCSE:NZYM B, NAS:NKTR, XBRU:UCB, NAS:BMRN, NAS:BIVV, HKSE:02269, NAS:JUNO, NAS:ALNY, NAS:BGNE, NAS:JAZZ, XMCE:GRF.P, NAS:BLUE, HKSE:01177, NAS:SGEN, NAS:AVXS, NAS:NBIX, NAS:ALKS, NAS:SAGE, NAS:EXEL » details
Traded in other countries:INCY.Austria, ICY.Germany,
Headquarter Location:USA
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which is licensed by Eli Lilly, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including IDO inhibitor epacadostat and next-generation JAK inhibitor itacitinib.

Top Ranked Articles about Incyte Corp

Lifshitz & Miller LLP Announces Investigation of ARMO BioSciences, Inc., Financial Engines, Inc., Globalstar, Inc., Gridsum Holding Inc., InnerWorkings, Inc., Incyte Corporation, PPG Industries, Inc., and Spectrum Brands Holdings, Inc.
FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
Detailed Research: Economic Perspectives on Voya Financial, Dominion Energy, Incyte, MeetMe, Ventas, and Select Medical — What Drives Growth in Today's Competitive Landscape
The Worst-Performing Stocks of 2018 Buffett is the largest stakeholder in one
Almost four months of 2018 have come and gone, leaving the S&P 500 index about flat despite some manic swings. According to the All-in-One Screener, 271 stocks of the index have failed to eke gains year to date. The stocks registering the worst performance are: L Brands Inc. (NYSE:LB), Incyte Corp. (NASDAQ:INCY), Acuity Brands Inc. (NYSE:AYI), The Kraft Heinz Co. (NASDAQ:KHC) and Kimco Realty Corp. (NYSE:KIM). Read more...
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY
Incyte, Merck Fall on Failed Late-Stage Study The skin cancer treatment did not meet primary objectives
Pharmaceutical company Incyte Corp. (NASDAQ:INCY) announced on Friday that its skin cancer drug, in combination with Merck & Co. Inc. (NYSE:MRK)'s Keytruda, failed to meet its primary objective in a late-stage study, sending shares of both companies lower. Read more...
Spring Forecast: Stocks to Buy With Your Tax Refund Investing your tax refund: best buys for spring
The stock market has been off to a rough start in 2018, with many speculating about a potential crash or a bear market. On closer inspection, though, it seems clear that the market is simply undergoing a typical correction in the wake of an earlier bull market. This is a natural trend and part of stabilizing the market for further investment – and makes it safe for investors to start wondering what stocks are good contenders for spring investments. Read more...
Analysts Take Action on Health Care Stocks Incyte, Illumina and Medtronic upgraded, Johnson & Johnson and Edwards Lifesciences downgraded
Analysts took action on health care stocks this week. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 69.93
INCY's Forward PE Ratio is ranked lower than
99% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. INCY: 69.93 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 9.14
INCY's PB Ratio is ranked lower than
82% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. INCY: 9.14 )
Ranked among companies with meaningful PB Ratio only.
INCY' s PB Ratio Range Over the Past 10 Years
Min: 8.09  Med: 48.69 Max: 391.93
Current: 9.14
8.09
391.93
PS Ratio 9.63
INCY's PS Ratio is ranked lower than
52% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INCY: 9.63 )
Ranked among companies with meaningful PS Ratio only.
INCY' s PS Ratio Range Over the Past 10 Years
Min: 7.17  Med: 20.67 Max: 239.71
Current: 9.63
7.17
239.71
Price-to-Free-Cash-Flow 10032.86
INCY's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. INCY: 10032.86 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
INCY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.24  Med: 208.22 Max: 13461.43
Current: 10032.86
7.24
13461.43
Price-to-Operating-Cash-Flow 142.17
INCY's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. INCY: 142.17 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INCY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.19  Med: 163.83 Max: 852.8
Current: 142.17
7.19
852.8
EV-to-EBIT -89.62
INCY's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. INCY: -89.62 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8534.9  Med: -10.45 Max: 1569.2
Current: -89.62
-8534.9
1569.2
EV-to-EBITDA -133.73
INCY's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. INCY: -133.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
INCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8534.9  Med: -12.3 Max: 1569.2
Current: -133.73
-8534.9
1569.2
EV-to-Revenue 8.95
INCY's EV-to-Revenue is ranked higher than
53% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. INCY: 8.95 )
Ranked among companies with meaningful EV-to-Revenue only.
INCY' s EV-to-Revenue Range Over the Past 10 Years
Min: 7.5  Med: 21 Max: 273.2
Current: 8.95
7.5
273.2
Current Ratio 3.86
INCY's Current Ratio is ranked lower than
52% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. INCY: 3.86 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.66 Max: 21.14
Current: 3.86
1.51
21.14
Quick Ratio 3.84
INCY's Quick Ratio is ranked higher than
51% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. INCY: 3.84 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.66 Max: 21.14
Current: 3.84
1.51
21.14
Days Inventory 18.76
INCY's Days Inventory is ranked higher than
88% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. INCY: 18.76 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 14.49  Med: 35.36 Max: 323.15
Current: 18.76
14.49
323.15
Days Sales Outstanding 52.38
INCY's Days Sales Outstanding is ranked higher than
51% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. INCY: 52.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 52.27 Max: 6447.52
Current: 52.38
12.25
6447.52
Days Payable 326.87
INCY's Days Payable is ranked higher than
89% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. INCY: 326.87 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 310.77  Med: 1723.24 Max: 32457.1
Current: 326.87
310.77
32457.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.30
INCY's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. INCY: -7.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INCY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.8  Med: -8.4 Max: -0.6
Current: -7.3
-17.8
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 30.14
INCY's Price-to-Net-Cash is ranked lower than
87% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. INCY: 30.14 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INCY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.43  Med: 7.89 Max: 450
Current: 30.14
1.43
450
Price-to-Net-Current-Asset-Value 18.78
INCY's Price-to-Net-Current-Asset-Value is ranked lower than
85% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. INCY: 18.78 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INCY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.23  Med: 9.3 Max: 3615
Current: 18.78
1.23
3615
Price-to-Tangible-Book 11.99
INCY's Price-to-Tangible-Book is ranked lower than
82% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. INCY: 11.99 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INCY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.91  Med: 6.4 Max: 340.56
Current: 11.99
0.91
340.56
Price-to-Intrinsic-Value-Projected-FCF 11.15
INCY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
79% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. INCY: 11.15 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
INCY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 9.91  Med: 25.57 Max: 138.66
Current: 11.15
9.91
138.66
Price-to-Median-PS-Value 0.46
INCY's Price-to-Median-PS-Value is ranked higher than
76% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. INCY: 0.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INCY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.83 Max: 10.64
Current: 0.46
0.11
10.64
Earnings Yield (Greenblatt) % -1.12
INCY's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. INCY: -1.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INCY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -37.7  Med: -1.1 Max: 1.3
Current: -1.12
-37.7
1.3

More Statistics

Revenue (TTM) (Mil) $1,534.42
EPS (TTM) $ -0.80
Beta1.17
Volatility33.40%
52-Week Range $60.23 - 140.11
Shares Outstanding (Mil)211.97

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 1,731 2,063 2,397
EBIT (Mil $) 222 529 918
EBITDA (Mil $) 265 587 982
EPS ($) 0.82 2.39 3.83
EPS without NRI ($) 0.82 2.39 3.83
EPS Growth Rate
(Future 3Y To 5Y Estimate)
63.68%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}